Condition 1: IBD (Crohn's disease). Condition 2: IBD (Ulcerative colitis). Crohn's disease [regional enteritis] Ulcerative colitis
Conditions
Interventions
Intervention 1: Intervention group: Participants will receive the commercial formulation of Mesalazine in combination with a capsule containing 50 mg of curcumin solid dispersion, administered three t
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: New case or flare-up patients. Mild to moderate ulcerative colitis diagnosis with elevated fecal calprotectin.
Exclusion criteria
Exclusion criteria: the use of any immunosuppressive or anti-inflammatory medications in the past two weeks hemoglobin less than 10 g/dl presence of leukopenia thrombocytopenia liver and kidney dysfunction Comorbid conditions include heart failure, chronic pancreatitis, diabetes mellitus, malignancies, active infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of fecal calprotectin. Timepoint: At baseline, one month, and two months after the initiation of solid dispersion curcumin pellet consumption. Method of measurement: Fecal calprotectin test. | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR (Erythrocyte Sedimentation Rate), CRP (C-reactive Protein). Timepoint: ?? ???? ??? ???? ?? ??? ? ?? ??? ??? ?? ???? ???? ??? ??? ???? ???????? ???? ????????. Method of measurement: SCCAI (Simple Clinical Colitis Activity Index) score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Abbaspour
Mashhad University of Medical Sciences
Outcome results
None listed